E2112-Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor-positive advanced breast cancer represent a death knell?
作者信息
Zhang Liyi
机构信息
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
出版信息
Thorac Cancer. 2022 May;13(9):1237-1239. doi: 10.1111/1759-7714.14399. Epub 2022 Mar 29.
Abstract
摘要
相似文献
1
E2112-Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor-positive advanced breast cancer represent a death knell?E2112-激素受体阳性晚期乳腺癌中内分泌治疗联合组蛋白去乙酰化酶抑制剂的III期试验阴性意味着敲响丧钟吗？
Thorac Cancer. 2022 May;13(9):1237-1239. doi: 10.1111/1759-7714.14399. Epub 2022 Mar 29.
2
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.CDK4/6 抑制剂治疗激素受体阳性、HER2 阴性、晚期或转移性乳腺癌患者：美国食品和药物管理局的汇总分析。
Lancet Oncol. 2020 Feb;21(2):250-260. doi: 10.1016/S1470-2045(19)30804-6. Epub 2019 Dec 16.
3
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.图昔替尼联合依西美坦治疗绝经后激素受体阳性晚期乳腺癌患者（ACE）的随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27.
4
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.绝经后激素受体阳性、HER2 阴性转移性乳腺癌患者的内分泌治疗与化疗：系统评价和网络荟萃分析。
Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4.
5
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.在绝经后 HR(+)、HER2(-)晚期乳腺癌中，双重阻断可改善无进展生存期，迎来新纪元。
Cancer Treat Rev. 2015 Feb;41(2):94-104. doi: 10.1016/j.ctrv.2014.12.011. Epub 2014 Dec 30.
6
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.帕博西尼联合戈舍瑞林与卡培他滨用于激素受体阳性、HER2 阴性转移性乳腺癌绝经前妇女（KCSG-BR15-10）：一项多中心、开放标签、随机、2 期临床试验。
Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24.
7
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.接受细胞周期蛋白依赖性激酶 4/6 抑制剂联合氟维司群治疗的激素受体阳性、HER2 阴性、晚期或转移性乳腺癌患者的总生存期：美国食品和药物管理局的汇总分析。
Lancet Oncol. 2021 Nov;22(11):1573-1581. doi: 10.1016/S1470-2045(21)00472-1. Epub 2021 Oct 14.
8
Design of SERENA-6, a phase III switching trial of camizestrant in -mutant breast cancer during first-line treatment.SERENA-6 设计：一线治疗中卡培昔替尼治疗 - 突变型乳腺癌的 III 期切换试验。
Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18.
9
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.帕博西尼：一种用于激素受体阳性晚期乳腺癌的新型细胞周期蛋白依赖性激酶抑制剂。
Ann Pharmacother. 2015 Nov;49(11):1252-60. doi: 10.1177/1060028015602273. Epub 2015 Aug 31.
10
The clinical benefit of epidermal growth factor receptor and human epidermal growth factor receptor 2 targeted agents adding to endocrine therapy in hormone receptor-positive breast cancer.表皮生长因子受体和人表皮生长因子受体2靶向药物联合内分泌治疗激素受体阳性乳腺癌的临床获益。
J Cancer Res Ther. 2018;14(Supplement):S218-S223. doi: 10.4103/0973-1482.183190.
引用本文的文献
1
2
Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth.双重靶向 class I HDAC 抑制剂和 ATM 激活剂 SP-1-303，优先抑制雌激素受体阳性乳腺癌细胞生长。
PLoS One. 2024 Jul 15;19(7):e0306168. doi: 10.1371/journal.pone.0306168. eCollection 2024.
本文引用的文献
1
Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020.全球乳腺癌发病和死亡模式：基于 2000 年至 2020 年癌症登记处数据的分析。
Cancer Commun (Lond). 2021 Nov;41(11):1183-1194. doi: 10.1002/cac2.12207. Epub 2021 Aug 16.
2
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.E2112：内分泌治疗联合恩替诺特或安慰剂治疗激素受体阳性晚期乳腺癌的随机 III 期试验。ECOG-ACRIN 癌症研究组的一项试验。
J Clin Oncol. 2021 Oct 1;39(28):3171-3181. doi: 10.1200/JCO.21.00944. Epub 2021 Aug 6.
3
Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020.中国癌症发病率、死亡率和疾病负担的变化趋势分析：基于 2020 年全球公布的流行病学数据与美国和英国的比较
Cancer Commun (Lond). 2021 Oct;41(10):1037-1048. doi: 10.1002/cac2.12197. Epub 2021 Jul 20.
4
KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression.KDELR2 通过 HDAC3 介导的细胞周期进程促进乳腺癌增殖。
Cancer Commun (Lond). 2021 Sep;41(9):904-920. doi: 10.1002/cac2.12180. Epub 2021 Jun 19.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).第五届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 5）
Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23.
7
Cancer burden of major cancers in China: A need for sustainable actions.中国主要癌症的癌症负担：需要采取可持续行动。
Cancer Commun (Lond). 2020 May;40(5):205-210. doi: 10.1002/cac2.12025. Epub 2020 May 2.
8
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.图昔替尼联合依西美坦治疗绝经后激素受体阳性晚期乳腺癌患者（ACE）的随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27.
9
Entinostat: a promising treatment option for patients with advanced breast cancer.恩替诺特：晚期乳腺癌患者有希望的治疗选择。
Future Oncol. 2017 Jun;13(13):1137-1148. doi: 10.2217/fon-2016-0526. Epub 2017 Mar 9.
10
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.晚期雌激素受体阳性乳腺癌治疗进展。
Lancet. 2017 Jun 17;389(10087):2403-2414. doi: 10.1016/S0140-6736(16)32419-9. Epub 2016 Dec 7.
Zotero 插件